Citation only
via OpenAlex
Update on emerging drugs for sarcopenia – age-related muscle wasting
Expert Opinion on Emerging Drugs · 2008 · ▲ 36 citations
Abstract
UNLABELLED: Sarcopenia - the progressive loss of muscle mass with advancing age is characterised by a deterioration of muscle quantity and quality leading to a gradual slowing of movement and a decline in strength and power. Sarcopenia is a highly significant public health problem. Frail elders often require assistance for accomplishing even basic tasks of independent living, and they are also at increased risk of serious injury from sudden falls and subsequent fractures. Since these age-related changes are largely attributed to the complex interaction of factors affecting neuromuscular transmission, muscle architecture, fibre composition, excitation-contraction coupling, and metabolism, the mechanisms responsible for these deleterious changes present numerous therapeutic targets for novel drug discovery. OBJECTIVE: This review provides an update on some of the emerging drugs for sarcopenia that have been in development during 2005 - 2008. METHODS: This is a review of the current status of emerging therapies and novel approaches for sarcopenia. RESULTS: Considerable research and development in academic and research institutions and in large and small pharma is being directed to sarcopenia and related health issues; specifically the development and evaluation of novel therapeutic strategies to attenuate, prevent, or ultimately reverse age-related muscle wasting and weakness. CONCLUSIONS: Few, if any, drugs have been developed for sarcopenia specifically, but there are many existing and emerging drugs that have potential application for tackling age-related muscle wasting, particularly drugs for neurodegenerative diseases.
◌ CITATION ONLY
Full text is not openly licensed for redistribution here. Read it at the source:
Provenance
- Source
- OpenAlex
- DOI
- 10.1517/14728210802544476
- Canonical
- link ↗
- Fetched
- 2026-10-17 MST
Cite this
APA
Lynch, G.S. (2008). Update on emerging drugs for sarcopenia – age-related muscle wasting. <em>Expert Opinion on Emerging Drugs</em>. https://doi.org/10.1517/14728210802544476
Vancouver
Lynch GS. Update on emerging drugs for sarcopenia – age-related muscle wasting. Expert Opinion on Emerging Drugs. 2008. doi:10.1517/14728210802544476.
BibTeX
@article{gordon2008Update,
title = {Update on emerging drugs for sarcopenia – age-related muscle wasting},
author = {Gordon Stuart Lynch},
journal = {Expert Opinion on Emerging Drugs},
year = {2008},
doi = {10.1517/14728210802544476},
}
Research neighborhood
References, citing works, and semantically nearest findings. Click a node to open it.
Related findings
Expert Opinion on Emerging Drugs 2004
Citation only
Emerging drugs for sarcopenia: age-related muscle wasting
Expert Opinion on Therapeutic Patents 2002
Citation only
Novel therapies for sarcopenia: ameliorating age-related changes in skeletal muscle
Frontiers in Bioscience-Landmark 2025
Open access · CC-BY
Molecular Pathogenesis of Sarcopenia: Regulatory Networks Involving MicroRNAs in Age-Related Skeletal Muscle Decline
Springer eBooks 2010
Citation only
Sarcopenia – Age-Related Muscle Wasting and Weakness
Sports Health A Multidisciplinary Approach 2013
Preprint · OA
Muscle Changes in Aging: Understanding Sarcopenia
Springer eBooks 2007
Citation only